You are viewing: China Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The China Recombinant Proteins Market was valued at $55.7 Million in 2023 and projected to reach to $87.1 Million by 2028, representing a compound annual growth rate of 9.3%. China's recombinant proteins market is positioned for accelerated growth through 2028, driven by increasing healthcare spending and the rising prevalence of chronic diseases requiring advanced biopharmaceutical interventions.

China Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Recombinant Proteins Market Trends and Insights

  • This robust expansion in China is driven by increasing demand for biopharmaceuticals, rising healthcare expenditure, and growing adoption of recombinant protein therapeutics across therapeutic areas including oncology, immunology, and rare diseases.
  • China's position as a major hub for biomanufacturing and its supportive regulatory environment continue to accelerate market penetration. The recombinant proteins market in China is benefiting from substantial investments in research and development, coupled with government initiatives to strengthen the domestic biotech ecosystem.
  • China's pharmaceutical companies are increasingly developing and commercializing recombinant protein-based treatments, reducing reliance on imports and creating competitive pricing advantages.
  • The forecast period through 2028 anticipates sustained growth in China as healthcare modernization and patient access programs expand the addressable market for advanced protein therapeutics..

Key Market Statistics

  • CAGR (2023-2028) 9.3% CAGR
  • Market Size, 2023 ~USD 55.7 Million
  • Forecast, 2028 ~USD 87.1 Million
  • Country China

China Recombinant Proteins Market Overview

Market Valuation Growth :

China's recombinant proteins market reached $55.7 million in 2023 and is expected to grow to $87.1 million by 2028, demonstrating strong market momentum with a 9.3% CAGR, outpacing the global average of 7.2%.

Biopharmaceutical Demand Surge :

Increasing adoption of recombinant protein therapeutics across oncology, immunology, and other therapeutic areas is driving market expansion as Chinese healthcare providers seek advanced treatment options.

Healthcare Investment Acceleration :

Rising healthcare expenditure in China, coupled with government support for biopharmaceutical innovation, is creating favorable conditions for recombinant protein market development and commercialization.

Therapeutic Area Diversification :

Expanding applications of recombinant proteins across multiple therapeutic domains including oncology and immunotherapy are broadening market opportunities and driving sustained growth in China.

China Recombinant Proteins Market Dynamics

  • The market's 9.3% CAGR reflects strong demand for innovative protein-based therapeutics and growing adoption among Chinese healthcare institutions. Government initiatives supporting domestic biopharmaceutical development, combined with improving regulatory frameworks and manufacturing capabilities, will further strengthen market expansion.
  • As China continues to establish itself as a global biopharmaceutical hub, recombinant protein therapeutics will play an increasingly critical role in addressing unmet medical needs across oncology, immunology, and other therapeutic areas..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • China's recombinant proteins market is projected to grow from $55.7M (2023) to $87.1M (2028) at a 9.3% CAGR.
    • China's biomanufacturing capabilities and supportive regulatory environment position it as a key growth driver in Asia Pacific.
    • Rising healthcare expenditure and demand for advanced therapeutics are accelerating recombinant protein adoption across China.
    • China's domestic biotech companies are increasingly developing recombinant protein treatments, reducing import dependency and enhancing market competition.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    China Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028

    Segment20212022202320242025202620272028CAGR (%)
    ACADEMIC RESEARCH INSTITUTES34.135.237.740.64447.852.2578.6
    BIOTECHNOLOGY COMPANIES23.924.726.428.430.733.336.339.68.5
    CONTRACT RESEARCH ORGANIZATIONS12.61313.814.81617.318.820.58.2
    OTHER END USERS88.28.69.19.810.511.212.17
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES6769.474.480.387.194.8103.6113.38.8
    TOTAL145.61150.4160.84173.32187.57203.71222.19242.578.6

    Target Audience

    • Biopharmaceutical Companies : Manufacturers and developers of recombinant protein therapeutics need China-specific market data to assess market opportunity, plan product launches, and allocate R&D resources effectively.
    • Healthcare Investment Firms : Private equity and venture capital investors require detailed China market analysis to evaluate investment opportunities in recombinant protein companies and biopharmaceutical ventures.
    • Market Entry Consultants : Strategy and consulting firms advising clients on China expansion need localized market intelligence to develop go-to-market strategies and competitive positioning recommendations.
    • Healthcare Policy Makers : Government agencies and regulatory bodies in China benefit from market data to inform healthcare policy, biopharmaceutical incentives, and therapeutic priority-setting decisions.
    • Contract Research Organizations : CROs and clinical research providers need China market insights to identify growth opportunities, understand therapeutic demand, and align service offerings with market needs.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for China's recombinant proteins market with verified 9.3% CAGR projections through 2028, enabling accurate financial forecasting and investment decision-making.
    • Competitive Positioning Intelligence : Understand China-specific market dynamics, therapeutic area adoption rates, and regional growth drivers to benchmark competitive positioning against local and international biopharmaceutical players.
    • Strategic Market Entry Planning : Access detailed insights on China's healthcare expenditure trends, regulatory environment, and recombinant protein adoption patterns to inform market entry strategies and localization approaches.
    • Investment & Expansion Decisions : Leverage comprehensive China market data to justify capital allocation, identify high-growth therapeutic segments, and prioritize geographic expansion within Asia's largest biopharmaceutical market.
    • Stakeholder Communication : Present credible, data-backed market projections to investors, board members, and partners regarding China's recombinant protein market opportunity and long-term growth potential.

    Frequently asked questions

    What is the current size of China's recombinant proteins market?

    China's recombinant proteins market was valued at $55.7 million in 2023 and is expected to reach $87.1 million by 2028.

    What is the projected growth rate for recombinant proteins in China?

    China's recombinant proteins market is expected to grow at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2028.

    What factors are driving growth in China's recombinant proteins market?

    Key drivers include rising healthcare expenditure, increasing demand for biopharmaceuticals, government support for biotech development, and expanding patient access programs across China.

    How does China's recombinant proteins market compare to global trends?

    China's 9.3% CAGR outpaces the global market growth rate of 7.2%, reflecting stronger regional demand and investment in biopharmaceutical innovation.

    What therapeutic areas are driving recombinant protein demand in China?

    Primary therapeutic areas include oncology, immunology, and rare diseases, where recombinant protein therapeutics are increasingly adopted across China's healthcare system.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Medical Association (AMA), Recombinant Antibody Network (RAN) National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Department of Agriculture (USDA), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), Institute for Molecular Medicine, Annual Reports, SEC Filings, Press Releases, Company Websites, Investor Presentations, Magazines, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global recombinant proteins market, which was validated through primary research.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the recombinant proteins market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The major players in the industry and market have been identified through extensive primary and secondary research.
    • The revenues generated from the recombinant proteins service business of players operating in the market have been determined through secondary research and primary analysis.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Global Recombinant proteins Market Size :Bottom-Up Approach

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Top-Down Approach

    Recombinant proteins Market Size, and Share

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    • Recombinant proteins are manipulated forms of proteins that are generated by recombinant DNA technology which modifies the gene sequences. These are formed by transfecting foreign genes into a host cell. They are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses.

    Key Stakeholders

    • Pharmaceutical and biotechnology companies
    • Life sciences companies
    • Academic research institutes
    • Government institutes
    • Private research firms
    • Contract Research Organizations (CROs)
    • Third-party suppliers, direct suppliers, distributors, and channel partners
    • Venture capitalists and investors
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market by product, application, host cell, end user, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa.
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships and research & development activities.
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

    Product Analysis

    • Product matrix, which provides a detailed comparison of the product portfolio of each company in the recombinant proteins Market

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status